Venus Medtech, the Chinese transcatheter aortic valve technology specialist, has made its second international acquisition as it pursues its strategy for global expansion in the TAVR market.

Transcatheter Technologies GMBH is preparing to enter the $1.5-1.6 billion Endovascular Aortic Repair market with a product that it says offers advantages over devices that are already available.

Transcatheter Technologies GMBH is preparing to enter the $1.5-1.6 billion Endovascular Aortic Repair market with a product that it says offers advantages over devices that are already available.

The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.